CD8⁺ T-cell subset composition of CD19-CAR–modified standard and T_SCM-enriched products. (A) Flow cytometry analyses of cells from a representative healthy donor (HD) at different steps of the 9-day manufacturing processes for the generation of CD19-CAR–modified standard and T_SCM-enriched products. Data are shown after gating on live cells (left panels) or live CD3⁺ T cells (right panels). Numbers indicate the percentage of cells in each gate. (B) Fold expansion of CD19-CAR–modified T cells generated under standard and T_SCM-enriched culture conditions. Data represent results from 6 HD; mean value ± SEM is indicated (*P < .05; Wilcoxon matched-pairs signed rank test). (C) Percentage of CD19-CAR–transduced T cells in standard and T_SCM-enriched products. Data represent results from 6 HDs; mean value ± SEM is indicated. (D) Percentage of CD8⁺ T-cell subsets in the CD19-CAR–modified standard and T_SCM-enriched products. T_SCM were defined as CD3⁺CD8⁺CD45RO⁻CCR7⁺CD45RA⁺CD62L⁺CD27⁺CD95⁺ cells; T_CM as CD3⁺CD8⁺CCR7⁺CD45RO⁺; T_EM as CD3⁺CD8⁺CCR7⁻CD45RO⁺; T_TE as CD3⁺CD8⁺CCR7⁻CD45RO⁻; other cells as CD3⁺CD8⁺CCR7⁺CD45RO⁻ not displaying the full T_SCM phenotype. Data representing results from 6 HDs are shown as box-and-whisker plots extending to minimum and maximum values. Bands inside the box represent median values. (E) Theoretical number of CD19-CAR⁺CD8⁺ T_SCM obtainable from stimulation of 1 × 10⁸ PBMCs (standard products) or Fab-streptamer–enriched CD8⁺ T_N (T_SCM-enriched products). Data represent results from 6 HDs (*P < .05; Wilcoxon matched-pairs signed rank test).